A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Trial Profile

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CELESTIAL
  • Sponsors Exelixis
  • Most Recent Events

    • 28 Mar 2018 According to an Ipsen media release, based on the results of this trial, Ipsen has announced that the European Medicines Agency (EMA) has validated the filing of a new application for Cabometyx, for treatment of patients with previously treated advanced Hepatocellular Carcinoma (HCC).
    • 15 Mar 2018 According to an Exelixis media release, the company has completed the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for CABOMETYX (cabozantinib) tablets as a treatment for patients with previously treated advanced hepatocellular carcinoma (HCC). The sNDA submission is based on results from this trial.
    • 26 Feb 2018 According to an Exelixis media release, positive top-line results were presented at the Advanced Hepatocellular Carcinoma (HCC) Presented at American Society of Clinical Oncology (ASCO) 2018 Gastrointestinal Cancers Symposium (ASCO-GI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top